BIT 3.03% 3.4¢ biotron limited

$10 Billion Deal, page-6282

  1. 20,220 Posts.
    lightbulb Created with Sketch. 1782
    According to this, the answer is, some viral infections not all.
    Read the whole thing, it is a good read.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC503779/

    Abstract

    Among the most cost-effective strategies for preventing viral infections, vaccines have proven effective primarily against viruses causing acute, self-limited infections. For these it has been sufficient for the vaccine to mimic the natural virus. However, viruses causing chronic infection do not elicit an immune response sufficient to clear the infection and, as a result, vaccines for these viruses must elicit more effective responses — quantitative and qualitative — than does the natural virus. Here we examine the immunologic and virologic basis for vaccines against three such viruses, HIV, hepatitis C virus, and human papillomavirus, and review progress in clinical trials to date. We also explore novel strategies for increasing the immunogenicity and efficacy of vaccines.
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
3.4¢
Change
0.001(3.03%)
Mkt cap ! $30.67M
Open High Low Value Volume
3.4¢ 3.4¢ 3.3¢ $632 18.85K

Buyers (Bids)

No. Vol. Price($)
1 287617 3.3¢
 

Sellers (Offers)

Price($) Vol. No.
3.5¢ 37989 2
View Market Depth
Last trade - 13.36pm 19/07/2024 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.